Preparation of selective epoxide hydrolase II inhibitor
A cyclooxygenase and inhibitor technology, applied in the field of new pharmaceutical preparations, can solve problems such as the inability to provide cyclooxygenase 2 inhibitors
Image
Examples
example 1
[0049] While stirring, 3.976 mmol of rofecoxib was added to 100 ml of 2,5-bis-O-methyl-1,4:3,6 dianhydro-D-glucitol. The solution was stirred for an additional 15 minutes under aseptic conditions. The sterile-filtered solution is sealed in vials / ampoules.
example 2
[0051] While stirring, 3.976 mmol of rofecoxib was added to 80 ml of 2,5-bis-O-methyl-1,4:3,6 dianhydro-D-glucitol. Continue to stir the solution under aseptic conditions and add 20ml of water for injection. The solution (diluted to 100 ml with 2,5-bis-O-methyl-1,4:3,6 dianhydro-D-glucitol) was sterile filtered and sealed into vials / ampoules.
example 3
[0053] While stirring, 7.952 mmol of rofecoxib was added to 80 ml of 2,5-bis-O-methyl-1,4:3,6 dianhydro-D-glucitol. The solution was continuously stirred under aseptic conditions and 20ml of water for injection was added. The solution (diluted to 100 ml with 2,5-bis-O-methyl-1,4:3,6 dianhydro-D-glucitol) was sterile filtered and sealed into vials / ampoules.
PUM
Login to View More Abstract
Description
Claims
Application Information
- IPC
- A61K9/08; A61K31/415; A61K31/42; A61K47/26
- Inventors
- 迪内希尚蒂拉尔·帕特尔; 萨钦迪内希·帕特尔